BEST3

Across TCGA pan-cancer cohorts, BEST3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BEST3 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher BEST3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BEST3 expression acts as an unfavorable survival marker.

PAAD, UCEC, and LUSC are the cancer types where BEST3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.132	0.613	.002	15	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
LUSC	OS	Median	All	0.274	0.729	.011	9	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
SKCM	DFS	Median	All	0.552	0.743	.011	4	view →
COAD	DFS	Median	All	0.258	0.691	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BEST3–PAAD (OS)

Open the PAAD breakdown →